Amundi Pioneer Asset Management Inc. Sells 472,164 Shares of Agilent Technologies, Inc. (NYSE:A)

Amundi Pioneer Asset Management Inc. reduced its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 16.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 2,343,313 shares of the medical research company’s stock after selling 472,164 shares during the quarter. Amundi Pioneer Asset Management Inc.’s holdings in Agilent Technologies were worth $277,644,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Norges Bank bought a new stake in shares of Agilent Technologies during the 4th quarter worth $358,609,000. Parnassus Investments CA lifted its holdings in shares of Agilent Technologies by 0.7% during the 4th quarter. Parnassus Investments CA now owns 2,684,170 shares of the medical research company’s stock worth $318,047,000 after acquiring an additional 17,690 shares during the last quarter. UBS Asset Management Americas Inc. lifted its holdings in shares of Agilent Technologies by 11.9% during the 4th quarter. UBS Asset Management Americas Inc. now owns 1,977,825 shares of the medical research company’s stock worth $234,352,000 after acquiring an additional 210,462 shares during the last quarter. Winslow Capital Management LLC lifted its holdings in shares of Agilent Technologies by 1,260.9% during the 4th quarter. Winslow Capital Management LLC now owns 1,963,381 shares of the medical research company’s stock worth $232,642,000 after acquiring an additional 1,819,111 shares during the last quarter. Finally, Nuveen Asset Management LLC lifted its holdings in shares of Agilent Technologies by 11.0% during the 4th quarter. Nuveen Asset Management LLC now owns 1,252,157 shares of the medical research company’s stock worth $148,368,000 after acquiring an additional 123,818 shares during the last quarter.

A number of brokerages recently commented on A. Wells Fargo & Company lifted their target price on shares of Agilent Technologies from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 17th. Redburn Partners upgraded shares of Agilent Technologies from a “neutral” rating to a “buy” rating in a research report on Friday, March 19th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell upgraded shares of Agilent Technologies from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $135.00 to $150.00 in a research report on Wednesday, March 24th. Mizuho began coverage on shares of Agilent Technologies in a research report on Tuesday, January 12th. They issued a “buy” rating and a $51.00 target price on the stock. Finally, Bank of America upgraded shares of Agilent Technologies from a “neutral” rating to a “buy” rating and set a $147.00 target price on the stock in a research report on Wednesday, February 17th. Nine investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $105.40.

In related news, CEO Michael R. Mcmullen sold 21,212 shares of the business’s stock in a transaction dated Monday, February 1st. The shares were sold at an average price of $120.26, for a total transaction of $2,550,955.12. Following the sale, the chief executive officer now owns 356,963 shares of the company’s stock, valued at $42,928,370.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Michael Tang sold 500 shares of the business’s stock in a transaction dated Thursday, January 14th. The stock was sold at an average price of $127.27, for a total transaction of $63,635.00. Following the sale, the senior vice president now directly owns 54,880 shares in the company, valued at approximately $6,984,577.60. The disclosure for this sale can be found here. Insiders have sold 22,712 shares of company stock worth $2,742,090 in the last quarter.

Shares of NYSE A opened at $129.34 on Thursday. Agilent Technologies, Inc. has a 1 year low of $72.75 and a 1 year high of $136.98. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.33 and a quick ratio of 1.84. The company’s 50-day moving average is $123.46 and its 200 day moving average is $116.46. The stock has a market capitalization of $39.41 billion, a P/E ratio of 56.24, a P/E/G ratio of 3.82 and a beta of 1.04.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Monday, February 15th. The medical research company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.17. Agilent Technologies had a net margin of 13.47% and a return on equity of 21.02%. The company had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter in the previous year, the company earned $0.81 earnings per share. Research analysts anticipate that Agilent Technologies, Inc. will post 3.67 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 28th. Investors of record on Tuesday, April 6th will be given a dividend of $0.194 per share. This represents a $0.78 annualized dividend and a dividend yield of 0.60%. The ex-dividend date is Monday, April 5th. Agilent Technologies’s dividend payout ratio is currently 23.78%.

Agilent Technologies declared that its Board of Directors has initiated a stock repurchase program on Tuesday, February 16th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to reacquire up to 5% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board believes its stock is undervalued.

About Agilent Technologies

Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.

Further Reading: Google Finance Portfolio Workaround

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.